Artemisinins: Promising drug candidates for the treatment of autoimmune diseases
Medicinal Research Reviews · 2024-03 · 44 (2) · 867-891
DOI: 10.1002/med.22001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 06.12.2023. Verfasst von Xu Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Artemisinins, Antimalarials, Autoimmune Diseases. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 126 Literaturangaben. Gefördert von: Shenzhen Key Laboratory of Inflammatory and Immunology Diseases, Scientific Research Foundation of Peking University Shenzhen Hospital.
Abstract (Originalsprache)
Autoimmune diseases are characterized by the immune system's attack on one's own tissues which are highly diverse and diseases differ in severity, causing damage in virtually all human systems including connective tissue (e.g., rheumatoid arthritis), neurological system (e.g., multiple sclerosis) and digestive system (e.g., inflammatory bowel disease). Historically, treatments normally include pain‐killing medication, anti‐inflammatory drugs, corticosteroids, and immunosuppressant drugs. However, given the above characteristics, treatment of autoimmune diseases has always been a challenge. Artemisinin is a natural sesquiterpene lactone initially extracted and separated from Chinese medicine Artemisia annua L., which has a long history of curing malaria. Artemisinin's derivatives such as artesunate, dihydroartemisinin, artemether, artemisitene, and so forth, are a family of artemisinins with antimalarial activity. Over the past decades, accumulating evidence have indicated the promising therapeutic potential of artemisinins in autoimmune diseases. Herein, we systematically summarized the research regarding the immunoregulatory properties of artemisinins including artemisinin and its derivatives, discussing their potential therapeutic viability toward major autoimmune diseases and the underlying mechanisms. This review will provide new directions for basic research and clinical translational medicine of artemisinins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China.
- Institute of Immunology and Inflammatory Diseases, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China.
- Shenzhen Key Laboratory of Inflammatory and Immunology Diseases, Shenzhen, China.
ORCID-Profile: Qingwen Wang, Jian Chen
Förderung
- Shenzhen Key Laboratory of Inflammatory and Immunology Diseases
- Scientific Research Foundation of Peking University Shenzhen Hospital
Zitieren
APA
Gao, X., Lin, X., Wang, Q., & Chen, J. (2024). Artemisinins: Promising drug candidates for the treatment of autoimmune diseases. Medicinal Research Reviews, 44(2), 867-891. https://doi.org/10.1002/med.22001
Vancouver
Gao X, Lin X, Wang Q, Chen J. Artemisinins: Promising drug candidates for the treatment of autoimmune diseases. Medicinal Research Reviews. 2024;44(2):867-891. doi:10.1002/med.22001
BibTeX
@article{Gao2024,
author = {Gao, Xu and Lin, Xian and Wang, Qingwen and Chen, Jian},
title = {Artemisinins: Promising drug candidates for the treatment of autoimmune diseases},
journal = {Medicinal Research Reviews},
year = {2024},
volume = {44},
number = {2},
pages = {867--891},
doi = {10.1002/med.22001}
}
EUVIMED